Big Week for #SYNGAP1: Trials, Data, #Epilepsy, Palo Alto & Athens #S10E216 Sunday, August 30, 2026 — Week 36 TRIALS & DATA — CAMP4, RARE-X + ProMMiS CAMP4 / CMP-002 Australia and Argentina cleared. EU and UK filings underway. First-in-human Phase 1/2 study still targeted for Q4 2026. CMP-002 is designed to increase expression of the healthy SYNGAP1 copy. CAMP4 raised another $50M and reports cash runway through the end of 2028. Q2 earnings / corporate update: investors.camp4tx.com/news-releases/news-release-details/camp4-reports-second-quarter-2026-financial-results-and Rare-X + ProMMiS Rare-X is our PRO partner for the ProMMiS Natural History Study. IMPORTANT: Families participating in ProMMiS need to complete their Rare-X surveys within SEVEN DAYS of their ProMMiS Natural History Study visit date. We need the patient/caregiver-reported data to line up with the clinical visit data. ProMMiS: curesyngap1.org/resources/studies/syngap1-prommis Rare-X: cureSYNG...